biopsy. The median interval between MRI and repeat biopsy was 2.6 months. Sixty-seven percent of men (57 of 86) showed at least one PIRADS 4 or 5 lesion. Twenty-seven (31%) of men had disease reclassification on confirmatory biopsy including seven men with Gleason 8 or 9 disease. 18.5% of men with no identifiable or PIRADS 1-3 lesions had grade reclassification compared with 42% of men with PIRADS 4 or 5 lesions. (p¼0.03). All grade reclassification in patients with lesions characterized as PIRADS 3 or less was from 3+3 to 3+4. Of the 42% of men with PIRADS 4 or 5 lesions who reclassified on confirmatory biopsy, 7/57 (12%) reclassified to Gleason 8 or 9 on confirmatory biopsy.
INTRODUCTION AND OBJECTIVES:
The Decipher test was extensively validated for the prediction of metastasis after radical prostatectomy, and has recently become available for use in biopsy specimens to aid in treatment selection for newly diagnosed patients. A recent study reported that patients with high-risk biopsy Decipher score (>0.60) had a 25% cumulative incidence of metastasis at 5 years postbiopsy. The objective of the current study was to examine the distribution of Decipher scores in a prospective biopsy population, including the proportion of low-and intermediate- for low-risk prostate cancer is increasingly utilized, however, whether men with GS 3+4 disease are appropriate candidates remains a matter of debate. We evaluated the effects of the initial Gleason grade on biopsy progression, treatment and outcomes after radical prostatectomy (RP). METHODS: We prospectively followed men on AS at our institution between 1990 and 2016. Those diagnosed with Gleason 3+3 or 3+4 were included. Life tables were used to estimate progressionfree survival (progression defined as increase in Gleason grade ¼3+4 or volume >33% positive cores or >50% single core), treatment-free survival, and PSA recurrence-free survival after delayed RP. Multivariate Cox proportional hazards regression was used to determine risk factors for progression, treatment and recurrence after RP. Multivariate logistic regression was used to determine risk factors for adverse pathology (defined as Gleason ¼4+3 or stage ¼pT3b or pN1) at RP. Models were adjusted for age, race, PSA density (PSAD), total number of biopsies and percentage of cores positive at diagnosis. RESULTS: We included 1,171 men with Gleason 3+3 or 3+4 on initial biopsy and ¼1 follow-up biopsy. A total of 1,056 (91%) had Gleason 3+3 and 106 (9%) 3+4. Patients with Gleason 3+4 had lower progression-free survival (20% vs 40%, p<0.01) by any biopsy criteria and treatment-free survival (52% vs 64%, p<0.01) at 5 years. Patients diagnosed with Gleason 3+3 who upgraded were at higher risk for treatment at 5 years than those with 3+4 and no upgrade (57% vs 37%, p<0.01). Risk factors for biopsy progression were initial Gleason 3+4 pathology (HR 1.4 95% CI 1.0-1.8) and PSAD (HR 1.7 95% CI 1.5-2.0), while total number of biopsies was associated with a lower risk (HR 0.7 95% CI 0.7-0.8). PSAD was a risk factor for treatment (HR 1.9 95% CI 1.6-2.3) while total biopsies (HR 0.6 95% CI 0.6-0.7) was associated with a lower risk. Among 333 men who underwent delayed RP, there was no significant difference between diagnostic 3+4 versus 3+3 in recurrence-free survival at 3 years (80% vs 90%, p¼0.23). Gleason 3+4 at diagnosis and/or subsequent biopsy upgrade was associated with adverse pathology at RP, when controlling for age, race, PSAD, total number of biopsies and number of cores positive.
CONCLUSIONS: While Gleason 3+4 at initial biopsy is a risk factor for progression and treatment on AS and adverse pathology at RP, it is not associated with PSA relapse after RP suggesting that such patients are suitable candidates for AS. However, longer e term follow up is ongoing.
